⌕
Novo Nordisk · NVO · NYSE
Tenet 62 · Solid
Compare
$40.70−2.16%At closeTenet 62 · Solid
$40.70−0.90 (−2.16%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$40.12−0.58 (−1.43%)
After hours: Nov 17, 2026, 7:57 PM ET

Novo Nordisk (NVO) Stock

Novo Nordisk (NVO) closed at $40.70 on Nov 17, 2026; its Tenet Score is 62 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

12 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$40.70
Nov 17, 2026
Market cap
$185.7B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
11.5×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
Dividend yield
2.80%
past year's regular dividends ÷ price · as of close, Nov 16, 2026
52-week range
35.12 – 64.16
low → high · as of close, Nov 16, 2026
Tenet Score
62/100
Solid · 340 Healthcare peers

Industry: Drugs

Novo Nordisk scores 62/100. Solid. Strongest on growth and quality, financial health is the soft spot, trading at 12× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
62/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
66
Quality
71
Health
37
Growth
75

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityBHealthDGrowthBMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
6.1×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
P/S
3.8×
price to sales, fiscal 2025 · as of close, Nov 16, 2026
ROE
64%
fiscal year to Dec 31, 2025
Operating margin
41.3%
before interest and tax
Net margin
33.1%
fiscal year to Dec 31, 2025
Current ratio
0.80
fiscal year to Dec 31, 2025
Net debt / EBITDA
—
Withheld: the balance sheet has no cash line, so enterprise value and net debt are not measured.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provid…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 35 US ETFs · top wrappers by weightSee all ETFs holding NVO →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

CompanyTenet ScoreMarket cap
Merck & Co IncMRK41$356.1B
Novartis AGNVS55$305.7B
AMGEN Inc.AMGN47$250.1B
Gilead Sciences, Inc.GILD38$207.9B
Pfizer Inc.PFE50$164.5B
Vertex Pharmaceuticals, Inc.VRTX55$136.4B
Bristol-Myers Squibb Co.BMY51$128.6B
GSK PlcGSK51$108.8B
Regeneron Pharmaceuticals, Inc.REGN64$98.5B
Moderna IncMRNA33$87.1B

Compare Novo Nordisk with

What sector and industry is Novo Nordisk in?

Novo Nordisk is in the Healthcare sector and the Drugs industry.

What is Novo Nordisk's Tenet Score?

Novo Nordisk's Tenet Score is 62 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.